P-354 - SBRT IN HIGH-INTERMEDIATE RISK PROSTATE CANCER
P-356 - SBRT IN NODAL OLIGORECURRENCE PROSTATE CANCER: BIOCHEMICAL PROGRESSION FREE SURVIVAL
P-375 - SOCIOECONOMIC IMPACT OF USING SBRT VERSUS CHHiP SCHEDULE IN EARLY STAGE PROSTATE CANCER
P-387 - STEREOTACTIC BODY RADIATION THERAPY IN OLIGOMETASTATIC PROSTATE CANCER
P-388 - STEREOTACTIC BODY RADIATION THERAPY WITH HELICAL-TOMOTHERAPY FOR ADRENAL METASTASES
P-389 - STEREOTACTIC BODY RADIOTHERAPY AS TREATMENT OF LYMPH NODE METASTASES.
P-390 - STEREOTACTIC BODY RADIOTHERAPY FOR ADRENAL GLAND METASTASES
P-398 - STEREOTACTIC RADIOTHERAPY AS A TECHNIQUE FOR RE-IRRADIATION IN PROSTATE CANCER.
P-407 - THE VALUE OF PET-TC PSMA IN PROSTATE CANCER SURVEILLANCE
P-411 - TOLERANCE AND EFFICACY OF APALUTAMIDE; PRELIMINARY RESULTS IN OUR CENTRE
P-413 - TOLERANCE OF EXTREME HYPOFRACTIONATION ON THE PRIMARY TUMOR IN MHSPC
P-424 - TREATMENT-RELATED ADVERSE EVENTS WITH APALUTAMIDE IN PROSTATE CANCER
P-426 - TRIMODALITY TREATMENT FOR MUSCLE-INVASIVE BLADDER CANCER
P-437 - VALOR DEL PET/TC-PSMA EN LA DECISIÓN TERAPÉUTICA DEL MCPRC
P-438 - Variability in bladder volume in prostate cancer radiotherapy.
P-444 - WEEKLY ULTRAFRACTIONATED RADIATION THERAPY FOR BLADDER CANCER IN THE ELDER.
P-447 - WHOLE-EXOME SEQUENCING ANALYSIS OF RADIOTHERAPY-INDUCED-RECTAL BLEEDING IN PROSTATE CANCER